Baidu
map

JCO:国际骨髓瘤工作组多发性骨髓瘤相关骨骼疾病治疗推荐规范

2013-06-08 JCO dxy

国际骨髓瘤工作组根据截至2012年8月份发表的相关文献,成立了一个由MM及骨髓瘤骨病方面的临床专家组成的跨学科委员会,最终形成该控制多发性骨髓瘤(MM)相关骨骼疾病的推荐规范。根据专家共识,对缺乏已发表文献的情况提出了其他推荐规范。推荐规范中相关实证级别及推荐等级均得到了委员会成员确定及批准。该推荐规范摘要如下: 推荐规范:对于所有接受抗骨髓瘤一线治疗的MM患者,无论根据传统的X摄像是否存在溶骨

国际骨髓瘤工作组根据截至2012年8月份发表的相关文献,成立了一个由MM及骨髓瘤骨病方面的临床专家组成的跨学科委员会,最终形成该控制多发性骨髓瘤(MM)相关骨骼疾病的推荐规范。根据专家共识,对缺乏已发表文献的情况提出了其他推荐规范。推荐规范中相关实证级别及推荐等级均得到了委员会成员确定及批准。该推荐规范摘要如下:

推荐规范:对于所有接受抗骨髓瘤一线治疗的MM患者,无论根据传统的X摄像是否存在溶骨病变,都应考虑使用双磷酸盐类药物(BP)。然而对于经核磁共振成像或正电子发射断层扫描/计算机断层扫描确定无骨骼疾病的患者,尚不清楚是否可通过BP获益。推荐静脉注射(IV)唑来膦酸(ZOL)或帕米膦酸(PAM)预防MM患者发生骨骼相关事件。鉴于ZOL具有潜在抗骨髓瘤效果及生存获益,对于MM新确诊患者优先推荐ZOL而非氯膦酸盐。在初始治疗期间,应每3至4周进行一次IV治疗。活跃期骨髓瘤患者应继续进行ZOL或PAM治疗,对于取得完全缓解或较佳部分缓解的患者,在暂停用药后出现病情复发,应重新进行ZOL或PAM治疗。尽管BP耐受性良好,但务必做好预防策略,以避免发生肾脏毒性或腭骨坏死。对于椎体性压缩骨折症状患者应考虑进行椎体后凸成形手术治疗。对于疼痛无法控制、行将发生病理性骨折或脊髓受压的患者,可通过低剂量放疗减轻相关症状。应就长骨骨折、脊髓受压及脊柱不稳等问题进行整形咨询。
 
International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma-Related Bone Disease.
Abstract
PURPOSEThe aim of the International Myeloma Working Group was to develop practice recommendations for the management of multiple myeloma (MM) -related bone disease.MethodologyAn interdisciplinary panel of clinical experts on MM and myeloma bone disease developed recommendations based on published data through August 2012. Expert consensus was used to propose additional recommendations in situations where there were insufficient published data. Levels of evidence and grades of recommendations were assigned and approved by panel members.RecommendationsBisphosphonates (BPs) should be considered in all patients with MM receiving first-line antimyeloma therapy, regardless of presence of osteolytic bone lesions on conventional radiography. However, it is unknown if BPs offer any advantage in patients with no bone disease assessed by magnetic resonance imaging or positron emission tomography/computed tomography. Intravenous (IV) zoledronic acid (ZOL) or pamidronate (PAM) is recommended for preventing skeletal-related events in patients with MM. ZOL is preferred over oral clodronate in newly diagnosed patients with MM because of its potential antimyeloma effects and survival benefits. BPs should be administered every 3 to 4 weeks IV during initial therapy. ZOL or PAM should be continued in patients with active disease and should be resumed after disease relapse, if discontinued in patients achieving complete or very good partial response. BPs are well tolerated, but preventive strategies must be instituted to avoid renal toxicity or osteonecrosis of the jaw. Kyphoplasty should be considered for symptomatic vertebral compression fractures. Low-dose radiation therapy can be used for palliation of uncontrolled pain, impending pathologic fracture, or spinal cord compression. Orthopedic consultation should be sought for long-bone fractures, spinal cord compression, and vertebral column instability.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1891066, encodeId=232d1891066fd, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Tue Apr 29 11:06:00 CST 2014, time=2014-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982731, encodeId=1d791982e313e, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Tue Jan 14 15:06:00 CST 2014, time=2014-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889566, encodeId=edec1889566d6, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Nov 01 17:06:00 CST 2013, time=2013-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5855, encodeId=6d5b585599, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c54c83759, createdName=dzmlife, createdTime=Tue Jul 02 16:32:00 CST 2013, time=2013-07-02, status=1, ipAttribution=)]
    2014-04-29 lidong40
  2. [GetPortalCommentsPageByObjectIdResponse(id=1891066, encodeId=232d1891066fd, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Tue Apr 29 11:06:00 CST 2014, time=2014-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982731, encodeId=1d791982e313e, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Tue Jan 14 15:06:00 CST 2014, time=2014-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889566, encodeId=edec1889566d6, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Nov 01 17:06:00 CST 2013, time=2013-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5855, encodeId=6d5b585599, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c54c83759, createdName=dzmlife, createdTime=Tue Jul 02 16:32:00 CST 2013, time=2013-07-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1891066, encodeId=232d1891066fd, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Tue Apr 29 11:06:00 CST 2014, time=2014-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982731, encodeId=1d791982e313e, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Tue Jan 14 15:06:00 CST 2014, time=2014-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889566, encodeId=edec1889566d6, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Nov 01 17:06:00 CST 2013, time=2013-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5855, encodeId=6d5b585599, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c54c83759, createdName=dzmlife, createdTime=Tue Jul 02 16:32:00 CST 2013, time=2013-07-02, status=1, ipAttribution=)]
    2013-11-01 jml2009
  4. [GetPortalCommentsPageByObjectIdResponse(id=1891066, encodeId=232d1891066fd, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Tue Apr 29 11:06:00 CST 2014, time=2014-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982731, encodeId=1d791982e313e, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Tue Jan 14 15:06:00 CST 2014, time=2014-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889566, encodeId=edec1889566d6, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Nov 01 17:06:00 CST 2013, time=2013-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5855, encodeId=6d5b585599, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c54c83759, createdName=dzmlife, createdTime=Tue Jul 02 16:32:00 CST 2013, time=2013-07-02, status=1, ipAttribution=)]
    2013-07-02 dzmlife

    厉害

    0

相关资讯

JCO:ASCO肿瘤患者静脉血栓防治推荐指南

在2013年5月20日在线出版的《临床肿瘤学杂志》(Journal of Clinical Oncology)上,美国临床肿瘤学会发布了最新版静脉血栓(VTE)防治推荐指南。该指南涉及内容包括门诊患者、住院患者和围手术期患者的预防,以及在针对肿瘤治疗过程中抗凝药物的治疗应用。 修订委员会对2007年12月至2012年期间,在MEDLINE及Cochrane联合图书馆上发表的相关文献进行了系统考察

FDA批准Kyprolis用于骨髓瘤治疗

FDA已经批准蛋白酶抑制剂carfilzomib(Kyprolis)用于接受过其他疗法但效果不佳的多发性骨髓瘤患者的治疗。批准该药用于至少两种已有疗法(其中之一必须为硼替佐米,Velcade)无效的复发性或难治性骨髓瘤患者的治疗。获得FDA加速审批程序1个月后,carfilzomib在肿瘤药物咨询委员会(ODAC)投票表决中得到了11:0(其中1票弃权)的高度认同,成功获得批准。“Kyprolis

Proceedings:梅奥诊所日前发布多发性骨髓瘤2013版诊疗指南

来自梅奥诊所癌症中心的研究人员近期发布了多发性骨髓瘤诊治指南。该指南针对尚未参加临床试验的新近诊断为多发性骨髓瘤(multiple myeloma,MM)的患者。该指南能帮助临床医生便于为患者提供初始治疗、干细胞移植以及维持治疗。该指南发表于近期的《梅奥医学进展》(Mayo Clinic Proceedings )杂志中,并且附带了来自明尼苏达洲、佛罗里达州以及阿利桑那州的梅奥癌症中心血液学家的一

Blood:II型糖尿病患者更易患血癌?!

       近日,来自米利亚姆医院的研究者运用一种新的综合分析技术分析表明,II型糖尿病病人存在20%患血癌的风险,如非霍奇金淋巴瘤、白血病和骨髓瘤。这项研究刊登在了Blood杂志上,研究数据为糖尿病和特定类型的癌症之间的联系提供了证据。        研究者Jorge Castill

Baidu
map
Baidu
map
Baidu
map